Condition
HFMD
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 4 (1)
Trial Status
Not Yet Recruiting1
Unknown1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07326878Phase 1Not Yet Recruiting
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
NCT07008755Not ApplicableRecruitingPrimary
Clinical Trial of Pegylated Interferon α-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .
NCT03519568Phase 4Unknown
Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine
Showing all 3 trials